Tang Capital Management LLC Purchases 1,500,000 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Tang Capital Management LLC boosted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 125.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,700,000 shares of the company's stock after buying an additional 1,500,000 shares during the period. Replimune Group makes up about 2.2% of Tang Capital Management LLC's portfolio, making the stock its 10th biggest holding. Tang Capital Management LLC owned about 3.95% of Replimune Group worth $32,697,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REPL. RTW Investments LP boosted its stake in shares of Replimune Group by 82.1% during the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after purchasing an additional 931,223 shares during the period. Redmile Group LLC raised its holdings in shares of Replimune Group by 2.6% during the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock worth $59,406,000 after purchasing an additional 124,344 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Replimune Group in the fourth quarter worth about $117,000. Point72 Asset Management L.P. acquired a new stake in Replimune Group during the fourth quarter valued at $3,439,000. Finally, ProShare Advisors LLC increased its stake in shares of Replimune Group by 33.8% during the fourth quarter. ProShare Advisors LLC now owns 20,788 shares of the company's stock worth $252,000 after purchasing an additional 5,247 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright boosted their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $19.43.

Replimune Group Price Performance

NASDAQ:REPL traded down $0.73 during mid-day trading on Wednesday, hitting $8.46. 2,888,834 shares of the company's stock traded hands, compared to its average volume of 917,949. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm's 50 day simple moving average is $8.75 and its 200 day simple moving average is $11.26. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a market cap of $651.55 million, a PE ratio of -2.76 and a beta of 0.68.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.